IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates

IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates Accessibility StatementSkip NavigationDisc Medicine investors who lost money after the FDA issued a Complete Response Letter for bitopertin are encouraged to contact Levi & KorsinskyNEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Disc Medicine, Inc. (NASDAQ: IRON) regarding whether the company adequately communicated risks regarding its bitopertin program before the FDA's issuance of a Com ...